Ganciclovir and Valganciclovir Use in Children

Marcia L. Buck, Pharm.D., FCCP, FPPAG


Pediatr Pharm. 2009;15(10) 

In This Article


Ganciclovir and valganciclovir have become standard components in most bone marrow or solid organ transplantation protocols for the prevention of CMV disease. Several recent studies describe their utility in the pediatric transplant population as well as in congenital and neonatal CMV infection.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: